Please provide your email address to receive an email when new articles are posted on . Older age was tied to a higher prevalence of 10 comorbidities among a group of 608 people with Cushing’s disease ...
The US Food and Drug Administration (FDA) has approved a new indication for osilodrostat (Isturisa, Recordati) as second-line treatment of endogenous hypercortisolemia in adults with Cushing syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback